More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]
Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]
I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval of Provenge, Zytiga, Jevtana, Xtandi and hopefully in the near future Radium-223 Dichloride (Alpharadin) we have many new treatment options [...]
One of the constant complaints I hear fro men with advanced prostate cancer that has become castrate resistant about Provenge (sipuleucel-T) is that the anticipated increase in overall survival is only 4.1 months and given the cost of $93,000 for the three infusions many men feel that cost does not justify the survival benefit. My [...]
Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]